1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
Galsky, M.D., Koshkin, V.S., Campbell, M.T., Drakaki, A., Bowman, I., Rose, A.A.N., Brown, J.R., Aragon-Ching, J.B., Gadde, S., Harandi, A., Rosenberg, J.E., Matsubara, N., Sokolowski, K.M., Ichimaru, M., Chan, S., Franco, S., Powles, T.B.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
HO-3867, STAT3 inhibitor: effects on cellular proliferation in hepatocellular carcinoma
Berger, N.G., Kunnimalaiyaan, S., Sokolowski, K.M., Gamblin, T.C., Kunnimalaiyaan, M.
Published in HPB (Oxford, England) (01.04.2017)
Published in HPB (Oxford, England) (01.04.2017)
Get full text
Journal Article